Atea Pharmaceuticals, Inc. AVIR
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Atea Pharmaceuticals, Inc. (AVIR) is a healthcare company listed in the US with a market value of about $345M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% below the current price.
About Atea Pharmaceuticals
Atea Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 1 of the last 8 years in our data. Its share count fell by 2% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351M | $49M | — | — |
| Net income | -$158M | -$168M | -$136M | -$116M | $121M | -$11M | -$14M | -$9M |
| Free cash flow | — | — | — | -$123M | -$87M | $297M | -$13M | -$8M |
| EPS (diluted) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 | $-0.51 | $-1.39 | $-0.90 |
| Net margin | — | — | — | — | 34.5% | -22.5% | — | — |
| ROIC | -63.0% | -34.6% | -23.3% | -19.7% | 17.0% | -1.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $9.00, 109% above the current price; targets range from $8.00 to $10.00; the consensus rating is “Buy”; expected EPS is $-1.68 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Atea Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Atea Pharmaceuticals pay a dividend?
Not currently.
Is Atea Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Atea Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.